Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOLDOPAM MESYLATE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
In-hospital, short-term (up to 48 hours) management of severe hypertension (hypertensive crisis) when rapid, but quickly reversible, blood pressure reduction is required,Off-label: Management of hypertensive emergencies with acute renal impairment
Hypertension
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via conjugation (glucuronidation and sulfation); CYP450 minimally involved.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 90% bound to plasma proteins, primarily albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.6–0.8 L/kg; moderate distribution consistent with limited tissue penetration.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Intravenous: 100%; no oral bioavailability due to extensive first-pass metabolism (not administered orally).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
No dose adjustment required for renal impairment; however, monitor for hypotension and electrolyte disturbances.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to increased risk of hypotension.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not FDA-approved for pediatric use; limited data: 0.2 mcg/kg/min IV infusion, titrated to effect; max 0.8 mcg/kg/min.
Not established; avoid use in children.
Start at low end of dosing range (0.1 mcg/kg/min) due to increased sensitivity to hypotension; monitor blood pressure closely.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No FDA black box warning.
None
Hypotension risk: Monitor blood pressure closely; may cause excessive hypotension.,Tachycardia: Can increase heart rate; caution in patients with coronary ischemia or tachyarrhythmias.,Glaucoma risk: May increase intraocular pressure; avoid in patients with glaucoma.,Hypokalemia: Monitor potassium levels; may cause hypokalemia.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Known hypersensitivity to fenoldopam or any component,Patients with glaucoma
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
No specific food interactions reported. However, patients should avoid excessive caffeine or stimulants as they may affect blood pressure.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for fetal hypotension and decreased uteroplacental perfusion; use only if clearly needed. Avoid in severe preeclampsia or eclampsia due to risk of significant maternal hypotension.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
No data on presence in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risk of infant exposure.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No standard dose adjustments required; but use lowest effective dose due to increased sensitivity to hypotensive effects in pregnancy. Titrate carefully.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Fenoldopam is a dopamine D1-like receptor agonist used for severe hypertension and hypertensive emergencies. It causes rapid, titratable blood pressure reduction without the toxic metabolites seen with nitroprusside. It also increases renal blood flow and natriuresis, making it beneficial in patients with renal impairment. Avoid in patients with glaucoma (increases intraocular pressure) or sulfite allergy (contains sodium metabisulfite).
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
This medication is given intravenously and is only used in a hospital setting.,You will have your blood pressure and heart rate monitored continuously during the infusion.,Report any headache, flushing, or dizziness to your nurse.,Do not stop the infusion suddenly; the dose will be gradually decreased.,Avoid consuming caffeine or other stimulants during treatment.,Tell your healthcare provider if you have glaucoma or a history of sulfite allergy.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
"Fenoldopam, a dopamine D1-like receptor agonist used for in-hospital blood pressure reduction, can potentiate the hypotensive and hypovolemic effects of the loop diuretic ethacrynic acid. Ethacrynic acid induces sodium and water diuresis, leading to reduced intravascular volume; Fenoldopam causes arterial vasodilation. When co-administered, the combined hemodynamic stress may increase the risk of excessive hypotension, renal hypoperfusion, and acute kidney injury, particularly in patients with compromised cardiac output or volume depletion."
"Iloprost, a prostacyclin analog, enhances vasodilation and inhibits platelet aggregation via IP receptor activation, increasing intracellular cAMP. Fenoldopam, a selective dopamine D1 receptor agonist, induces systemic and renal vasodilation through cAMP-dependent pathways. Concomitant use amplifies the hypotensive effect, potentially leading to severe hypotension, reflex tachycardia, and end-organ hypoperfusion, especially in patients with compromised cardiovascular reserve."
"Amlodipine, a dihydropyridine calcium channel blocker, reduces peripheral vascular resistance by inhibiting calcium influx into vascular smooth muscle cells. Fenoldopam, a selective dopamine D1 receptor agonist, causes arterial vasodilation, particularly in the renal and mesenteric beds. The concurrent use of these two vasodilatory agents leads to additive hypotension, potentially causing symptomatic drops in blood pressure, dizziness, and syncope, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOLDOPAM MESYLATE vs ALDORIL 25, answered by our medical review team.
FENOLDOPAM MESYLATE is a Antihypertensive that works by Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOLDOPAM MESYLATE and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOLDOPAM MESYLATE is: 0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOLDOPAM MESYLATE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOLDOPAM MESYLATE is classified as Category C. Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for feta. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.